Safety, Tolerability, and Pharmacokinetics of C2N-8E12 in Subjects With Progressive Supranuclear Palsy

Completed · Phase 1 · Has a placebo group

Conditions studied: Progressive Supranuclear Palsy

In brief

This study will evaluate the safety and tolerability (maximum tolerated dose (MTD) within the specified dosing range) of single intravenous (IV) infusion of C2N-8E12 in patients with progressive supranuclear palsy (PSP).

Key facts

Study ID

NCT02494024

Run by

C2N Diagnostics

People needed

32

Starts

2015-07-01

Expected to finish

2016-08-01

Last updated by the study team

2017-07-26

Who can join

Age: 50 and older, up to 85. Sex: any. Healthy volunteers: not accepted.

Where it is running

• University of Alabama — Birmingham, Alabama, United States
• Mayo Clinic — Scottsdale, Arizona, United States
• University of California, Los Angeles (UCLA) — Los Angeles, California, United States
• UCSD Department of Neurosciences — San Diego, California, United States
• University of California, San Francisco — San Francisco, California, United States
• University of Florida College of Medicine — Gainesville, Florida, United States
• Mayo Clinic — Jacksonville, Florida, United States
• Indiana University Medical Center — Indianapolis, Indiana, United States
• Mayo Clinic — Rochester, Minnesota, United States
• Columbia University — New York, New York, United States
• Vanderbilt University Medical Center — Nashville, Tennessee, United States
• Texas Health Presbyterian Dallas — Dallas, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.